Pediatric Casofungin

 

This reference library was created for the community of providers who care for children with these illnesses. It was developed to assist clinicians in understanding, diagnosing and treating pediatric invasive fungal infections. The library links to important references within each category but is not meant to be comprehensive. 

 

Return to Library Home

 

 

 

 

 

 

 

 

 

 

International Pediatric Fungal Network, Box 3499, Duke University Medical Center, Durham, NC 27710. USA.   Tel: 919-668-4847 Email: PFNContracts@duke.edu

Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis. 

Doring M et al. BMC Infect Dis. 2012 Jul 2;12:151.

Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infections. 

Wiederhold NP et al. Clin Med Insights Pediatr. 2012 Jun 7;6:19-31.

Caspofungin therapy in immunocompromised children and neonates. 

Somer A et al. Expert Rev Anti Infect Ther. 2011 Mar;9(3):347-55.


A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants. 

Mohamed WA et al. J Trop Pediatr. 2012 Feb;58(1):25-30.

Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients.

Li CC et al. Antimicrob Agents Chemother. 2011 May;55(5):2098-105.

Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients.

Groll AH et al. Antimicrob Agents Chemother. 2010 Oct;54(10):4143-9.

A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.

Maertens JA et al. Pediatr Infect Dis J. 2010 May;29(5):415-20.

Safety experience with caspofungin in pediatric patients. 

Zaoutis T et al. Pediatr Infect Dis J. 2009 Dec;28(12):1132-5.

Caspofungin: In pediatric patients with fungal infections. 

Garnock-Jones KP et al. Paediatr Drugs. 2009;11(4):259-69.

A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. 

Zaoutis TE et al. Pediatrics. 2009 Mar;123(3):877-84.

Caspofungin for the treatment of pediatric fungal infections. 

Fisher BT et al. Pediatr Infect Dis J. 2008 Dec;27(12):1099-102.

Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infections. 

Wiederhold NP et al. Clin Med Insights Pediatr. 2012 Jun 7;6:19-31.

Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. 

Döring M et al. BMC Infect Dis. 2012 Oct 19;12:263.

Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: An overview.

Lipp HP. Br J Clin Pharmacol. 2010 Oct;70(4):471-80.

Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer.

Bernardo VA et al. Ann Pharmacother. 2013 Jul-Aug;47(7-8):976-83.

Poor absorption of high-dose posaconazole in pediatric bone marrow transplant patients. 

Matthias KR et al. Ann Pharmacother. 2012 Sep;46(9):e22.

Retrospective survery on the off-label use of posaconazole in pediatric hematology patients.

Cesaro S et al. Eur J Clin Microbiol Infect Dis. 2011 Apr;30(4):595-6.